Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease
Launched by NITIN GOYAL · Jan 17, 2025
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a procedure called intracranial stenting, which is used to help patients who have had a stroke due to severe narrowing of blood vessels in the brain (known as intracranial atherosclerotic disease or ICAD). The goal is to create a registry that collects information about patients who undergo this procedure, looking closely at how it is done, the immediate outcomes, and the longer-term results. Researchers want to understand the best practices for treating these patients and how effective this treatment is.
To be eligible for this study, patients must be adults who have a significant narrowing (70-99%) of their blood vessels and have experienced a stroke, even after trying medications to manage their condition. They should have a modified Rankin Scale (mRS) score of 3 or less, which measures their ability to carry out daily activities. Participants can expect to provide information about their health and the procedure they undergo, and they will be followed up to see how they do after the stenting. It’s important to note that this study is not accepting participants yet, and it will not include patients who had a different type of stroke or those who have milder vessel narrowing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with ICAD resulting in 70-99% vessel stenosis who undergo PTAS with any device
- • Patients will have to experience a stroke despite medical management involving risk factor modification and an antiplatelet agent
- • Baseline modified Rankin Scale (mRS) ≤ 3
- • Performance of the endovascular procedure at least 3 days after the last stroke
- Exclusion Criteria:
- • Large vessel occlusion strokes undergoing rescue intracranial stenting will not be included
- • Baseline modified Rankin Scale (mRS) \>3
- • Performance of the endovascular procedure less than 3 days after the last stroke.
- • Patients undergoing intracranial stenting for first stroke caused by ICAD
- • Adult patients with ICAD resulting in \<70% vessel stenosis
About Nitin Goyal
Nitin Goyal is a dedicated clinical trial sponsor with expertise in advancing innovative therapeutic solutions through rigorous research and development. With a strong focus on patient safety and ethical standards, Nitin Goyal oversees clinical studies that aim to evaluate the efficacy and safety of novel treatments across various therapeutic areas. His commitment to collaboration and transparency fosters strong partnerships with research institutions and regulatory bodies, ensuring that clinical trials are conducted efficiently and in compliance with all relevant guidelines. Driven by a passion for improving patient outcomes, Nitin Goyal is at the forefront of clinical research, striving to bring groundbreaking therapies to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Memphis, Tennessee, United States
Patients applied
Trial Officials
Nitin Goyal, MD
Principal Investigator
Semmes Murphey Clinic
Violiza Inoa, MD
Principal Investigator
Semmes Murphey Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported